Literature DB >> 6326810

Purification and characterization of a human platelet cyclic nucleotide phosphodiesterase.

P G Grant, R W Colman.   

Abstract

A cyclic nucleotide phosphodiesterase was extensively purified from the 100000g supernatant fraction of human platelets. The purification was 2500-3000-fold with 30% recovery of activity. The enzyme was isolated by DEAE-cellulose chromatography followed by adsorption to blue dextran-Sepharose and elution with cAMP. The protein has a molecular weight of 140 000 as determined by gel filtration. On NaDodSO4-containing polyacrylamide gels the major band is at 61 000 daltons, suggesting that the enzyme may exist as a dimer in solution under nondenaturing conditions. The enzyme requires Mg2+ or Mn2+ for activity. The calcium binding protein calmodulin does not stimulate hydrolysis of cAMP by this enzyme. The purified enzyme hydrolyzes both cAMP and cGMP with normal Michaelis-Menten kinetics with Km values of 0.18 microM and 0.02 microM, respectively. The hydrolysis of cGMP, however, is only one-tenth as rapid as the hydrolysis of cAMP. Cyclic GMP does not stimulate cAMP hydrolysis but instead is a potent competitive inhibitor of cAMP hydrolysis. The enzyme is also competitively inhibited by the phosphodiesterase inhibitors papaverine, 3-isobutyl-l-methylxanthine, and dipyridamole. The enzyme did not cross-react with an antibody raised to a cAMP phosphodiesterase isolated from dog kidney, indicating that the enzymes are not immunologically related. The inhibition of cAMP hydrolysis by cGMP suggests a possible regulatory link between these two cyclic nucleotides. One of the roles of cGMP in platelets may be to potentiate increases in intracellular cAMP by inhibiting the hydrolysis of cAMP by this enzyme.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6326810     DOI: 10.1021/bi00303a034

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  25 in total

1.  Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts.

Authors:  M A Movsesian; C J Smith; J Krall; M R Bristow; V C Manganiello
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

2.  Evidence that insulin and isoprenaline activate the cGMP-inhibited low-Km cAMP phosphodiesterase in rat fat cells by phosphorylation.

Authors:  E Degerman; C J Smith; H Tornqvist; V Vasta; P Belfrage; V C Manganiello
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

3.  Evidence for the presence of essential histidine and cysteine residues in platelet cGMP-inhibited phosphodiesterase.

Authors:  F A Ghazaleh; G A Omburo; R W Colman
Journal:  Biochem J       Date:  1996-07-15       Impact factor: 3.857

4.  Immunological identification of the major platelet low-Km cAMP phosphodiesterase: probable target for anti-thrombotic agents.

Authors:  C H Macphee; S A Harrison; J A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

5.  Expression and mutagenesis of the catalytic domain of cGMP-inhibited phosphodiesterase (PDE3) cloned from human platelets.

Authors:  K M Tang; E K Jang; R J Haslam
Journal:  Biochem J       Date:  1997-04-01       Impact factor: 3.857

6.  cAMP-mediated phosphorylation of the low-Km cAMP phosphodiesterase markedly stimulates its catalytic activity.

Authors:  P G Grant; A F Mannarino; R W Colman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

7.  Effect of AD6 (8-monochloro-3-beta-diethylamino-ethyl-4-methyl-7-ethoxycarbonylme tho xy coumarin) on cyclic nucleotide phosphodiesterases in human platelets.

Authors:  G Hakim; D Fiorentini; A Falasca; M Prosdocimi; C A Rossi
Journal:  Experientia       Date:  1988-03-15

8.  Identification of overlapping but distinct cAMP and cGMP interaction sites with cyclic nucleotide phosphodiesterase 3A by site-directed mutagenesis and molecular modeling based on crystalline PDE4B.

Authors:  W Zhang; H Ke; A P Tretiakova; B Jameson; R W Colman
Journal:  Protein Sci       Date:  2001-08       Impact factor: 6.725

9.  Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases.

Authors:  R R Reinhardt; E Chin; J Zhou; M Taira; T Murata; V C Manganiello; C A Bondy
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

Review 10.  Cyclic nucleotide phosphodiesterases in the human lung.

Authors:  G Dent; H Magnussen; K F Rabe
Journal:  Lung       Date:  1994       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.